Large randomised studies of new long-acting medications for the prevention and treatment of HIV have shown high effectiveness and acceptability. Although modelling studies indicate these agents could be fundamental in HIV elimination, coordination of their entry into health-care markets is crucial, especially in low-income and middle-income countries with high HIV prevalence, where coordination is low despite UNAIDS flagging that global HIV targets will not be met. Research and implementation projects are tightly controlled by originator pharmaceutical companies, with only a small percentage of eligible people living with or affected by HIV benefiting from these projects. WHO, financial donors, manufacturers, and governments need to consider urgent coordinated action from stakeholders worldwide, akin to the successful introduction of dolutegravir into treatment programmes across low-income and middle-income countries. Without this immediate coordination, large-scale access to long-acting agents for HIV will be delayed, potentially extending into the 2030s. This delay is unacceptable considering the established global HIV targets.

中文翻译：

---

对长效 HIV 预防和治疗配方的漫长等待


关于预防和治疗 HIV 的新型长效药物的大型随机研究表明，这些药物具有很高的有效性和可接受性。尽管建模研究表明这些药物可能是消除 HIV 的基础，但协调它们进入医疗保健市场至关重要，尤其是在 HIV 流行率高的低收入和中等收入国家，尽管联合国艾滋病规划署表示无法实现全球 HIV 目标，但这些国家的协调水平很低。研究和实施项目受到原始制药公司的严格控制，只有一小部分符合条件的 HIV 感染者或受 HIV 影响的人从这些项目中受益。世卫组织、财政捐助者、制造商和政府需要考虑全球利益攸关方采取紧急协调行动，类似于将多替拉韦成功引入低收入和中等收入国家的治疗规划。如果没有这种立即协调，大规模获得长效 HIV 药物将延迟，并可能延续到 2030 年代。考虑到既定的全球 HIV 目标，这种延迟是不可接受的。